Revolution Medicines (FRA:42Z) Beta: 2.3306 (As of Jun. 26, 2026)


FRA:42Z Revolution Medicines Inc FRA:42Z
30 GF Score
Price €157.20
GF Value €0.39
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Revolution Medicines Beta?

Revolution Medicines FRA:42Z +6.47% 30 Beta is 2.3306 as of Jun. 26, 2026. GuruFocus rates FRA:42Z with a GF Score™ of 30/100 and a GF Value™ of €0.39 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), Revolution Medicines's Beta is 2.3306.


Revolution Medicines  (FRA:42Z) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Revolution Medicines Beta Related Terms


Revolution Medicines Beta Historical Data

* Premium members only.

The historical data trend for Revolution Medicines's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Revolution Medicines Beta Chart

Revolution Medicines Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 1.55 0.06 -0.60

Revolution Medicines Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.53 1.56 1.37 -0.60 1.46

FRA:42Z vs ONC, ALNY, RPRX: Beta Comparison

For the Biotechnology subindustry, Revolution Medicines's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revolution Medicines Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revolution Medicines's Beta distribution charts can be found below:

* The bar in red indicates where Revolution Medicines's Beta falls into.


FRA:42Z
30GF Score
Revolution Medicines Inc FRA:42Z
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Revolution Medicines Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 2.3306 mean?
Revolution Medicines (FRA:42Z) has a Beta of 2.3306 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Revolution Medicines and its competitors.
Is Revolution Medicines' Beta too high?
Revolution Medicines' current Beta is 2.3306. Overall, Revolution Medicines has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Revolution Medicines' Beta compare to ONC and ALNY?
Revolution Medicines' Beta of 2.3306 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Revolution Medicines and its competitors. Revolution Medicines's current Beta is 2.3306. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revolution Medicines stock overvalued right now?
Based on GuruFocus' analysis, Revolution Medicines (FRA:42Z) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.39, compared to a current price of €157.20 — trading 40207.7% above its estimated fair value. The current Beta is 2.3306. Revolution Medicines' overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Revolution Medicines (FRA:42Z), the current Beta is 2.3306 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Revolution Medicines (FRA:42Z) Overvalued in 2026?

Based on GuruFocus' analysis, Revolution Medicines stock appears to be overvalued. The current stock price of €157.20 is trading 40207.7% above its estimated GF Value™ of €0.39. GuruFocus considers Revolution Medicines to be Significantly Overvalued.

Key valuation signals for FRA:42Z:

  • Beta: 2.3306
  • GF Value™: €0.39 vs. price of €157.20 (40207.7% above fair value)
  • GF Score™: 30/100 with 4 warning signs

No single metric tells the full story. See the FRA:42Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Revolution Medicines Business Description

Address 700 Saginaw Drive, Redwood City, CA, USA, 94063
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
30GF Score

Get the complete analysis for FRA:42Z

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€157.20
Price
€0.39
GF Value